Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.37 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787073 | 0.82 | ALDH1A1 (0.32) | MEN1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL1656581 | 0.80 | HCAR2 (0.44) | HCAR2ESR1CYP2C9CYP2C8AKR1B1 | |
| SCHEMBL6794633 | 0.79 | KDM4E (0.33) | ALDH1A1 | |
| SCHEMBL6792714 | 0.78 | HCAR2 (0.55) | HCAR2ESR1CYP2C9CYP2C8AKR1B1 | |
| SCHEMBL881069 | 0.78 | HCAR2 (0.45) | HCAR2ESR2CYP2C9CYP2C8AKR1B1 | |
| Hydrochloric Acid SCHEMBL6793305 | 0.73 | CCNA2 (0.42) | — | |
| SCHEMBL6793511 | 0.72 | CDK2 (0.33) | ALDH1A1 | |
| SCHEMBL6793266 | 0.72 | MAPKAPK2 (0.41) | MEN1ALDH1A1KMT2A | |
| SCHEMBL6793002 | 0.70 | HCAR2 (0.41) | HCAR2ESR1ESR2CYP2C9CYP2C8 | |
| SCHEMBL6793335 | 0.70 | HCAR2 (0.49) | HCAR2ESR1ESR2CYP2C9CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | HCAR2 1767/4885ESR1 4622/4885ESR2 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.